Literature DB >> 2390433

Is cyclosporin A an inhibitor of drug metabolism?

G Li1, G Treiber, J Meinshausen, J Wolf, J Werringloer, U Klotz.   

Abstract

1. The potential for a drug interaction between cyclosporin A and midazolam was investigated since both compounds appear to be metabolized by the same cytochrome P-450 isoenzyme. 2. In vitro evaluation of the binding of cyclosporin A to rat microsomal cytochrome P-450 indicated a Ks-value of 0.4 microM. In further studies with rat liver microsomes IC50-values of 6, 8 and 70 microM cyclosporin A were determined for the inhibition of the metabolism of midazolam to its alpha-OH-,4-OH- and di-OH-metabolites, respectively. 3. Comparative studies with human liver microsomes indicated IC50-values of approximately 300 microM for the formation of alpha-OH-midazolam and of 65 microM for the formation of 4-OH-midazolam. 4. The pharmacokinetics of a single intravenous dose of midazolam (0.075 mg kg-1) was studied in nine patients receiving cyclosporin A to prevent rejection of their transplanted kidneys. The average steady state blood concentrations of cyclosporin A, measured by r.i.a. using a specific monoclonal antibody, varied during a dosing interval between 175 and 600 ng ml-1. 5. In these patients the hepatic elimination of midazolam was characterized by a mean t1/2 (+/- s.d.) of 2.3 +/- 1.2 h and a plasma clearance (CL) of 414 +/- 95 ml min-1. These values were not different from those of normal human subjects (t1/2 = 1.5 to 4 h, CL = 350 to 700 ml min-1). 6. From the results of the in vitro experiments it is concluded that cyclosporin A may potentially inhibit drug metabolism.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2390433      PMCID: PMC1368277          DOI: 10.1111/j.1365-2125.1990.tb03745.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  20 in total

1.  Measurement of substrate and inhibitor binding to microsomal cytochrome P-450 by optical-difference spectroscopy.

Authors:  C R Jefcoate
Journal:  Methods Enzymol       Date:  1978       Impact factor: 1.600

Review 2.  Metabolism of cyclosporine.

Authors:  G Maurer
Journal:  Transplant Proc       Date:  1985-08       Impact factor: 1.066

3.  Effect of cyclosporine on hepatic oxidative and conjugative metabolism in rats.

Authors:  R E Galinsky; D P Alexander; M R Franklin
Journal:  Drug Metab Dispos       Date:  1987 Sep-Oct       Impact factor: 3.922

4.  Characterization of a common genetic defect of cytochrome P-450 function (debrisoquine-sparteine type polymorphism)--increased Michaelis is Constant (Km) and loss of stereoselectivity of bufuralol 1'-hydroxylation in poor metabolizers.

Authors:  P Dayer; R Gasser; J Gut; T Kronbach; G M Robertz; M Eichelbaum; U A Meyer
Journal:  Biochem Biophys Res Commun       Date:  1984-11-30       Impact factor: 3.575

5.  The effects of cyclosporin A (CsA) on hepatic microsomal drug metabolism in the rat.

Authors:  J A Augustine; M A Zemaitis
Journal:  Drug Metab Dispos       Date:  1986 Jan-Feb       Impact factor: 3.922

6.  Physiologic and temporal variation in hepatic elimination of midazolam.

Authors:  U Klotz; G Ziegler
Journal:  Clin Pharmacol Ther       Date:  1982-07       Impact factor: 6.875

Review 7.  Clinical pharmacokinetics of cyclosporin.

Authors:  R J Ptachcinski; R Venkataramanan; G J Burckart
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

Review 8.  Midazolam: the first water-soluble benzodiazepine. Pharmacology, pharmacokinetics and efficacy in insomnia and anesthesia.

Authors:  J H Kanto
Journal:  Pharmacotherapy       Date:  1985 May-Jun       Impact factor: 4.705

Review 9.  Midazolam: pharmacology and uses.

Authors:  J G Reves; R J Fragen; H R Vinik; D J Greenblatt
Journal:  Anesthesiology       Date:  1985-03       Impact factor: 7.892

Review 10.  Midazolam. A review of its pharmacological properties and therapeutic use.

Authors:  J W Dundee; N J Halliday; K W Harper; R N Brogden
Journal:  Drugs       Date:  1984-12       Impact factor: 9.546

View more
  2 in total

1.  Cyclosporin A blocks bile acid synthesis in cultured hepatocytes by specific inhibition of chenodeoxycholic acid synthesis.

Authors:  H M Princen; P Meijer; B G Wolthers; R J Vonk; F Kuipers
Journal:  Biochem J       Date:  1991-04-15       Impact factor: 3.857

2.  Cyclosporine inhibition of hepatic and intestinal CYP3A4, uptake and efflux transporters: application of PBPK modeling in the assessment of drug-drug interaction potential.

Authors:  Michael Gertz; Catherine M Cartwright; Michael J Hobbs; Kathryn E Kenworthy; Malcolm Rowland; J Brian Houston; Aleksandra Galetin
Journal:  Pharm Res       Date:  2012-11-22       Impact factor: 4.200

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.